Rituximab Plus Lenalidomide Is as Effective as Immunochemotherapy in the Eradication of Molecular Disease in Untreated Follicular Lymphoma: Relevance Lysa Ancillary Study

Hematological Oncology - United Kingdom
doi 10.1002/hon.77_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Immunochemotherapy With Obinutuzumab or Rituximab in Previously Untreated Follicular Lymphoma in the Randomised Phase Iii Gallium Study: Analysis by Chemotherapy Regimen

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Results of Phase Ii Study of Combined Immunotherapy With Rituximab Plus Lymphokine-Activated Killer Cells as Maintenance in Follicular Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Bendamustine and Rituximab in Elderly Patients With Low-Tumour Burden Follicular Lymphoma. Results of the LYSA Phase II BRIEF Study

British Journal of Haematology
Hematology
2018English

The Immunologic Doublet of Lenalidomide Plus Obinutuzumab Is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/Ii Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Real World Data on Rituximab Maintenance Therapy After Frontline Immunochemotherapy in Grade 1-3a Follicular Lymphoma

British Journal of Haematology
Hematology
2017English

Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

Haematologica
Hematology
2015English

Phase Iiib Study of Lenalidomide Plus Rituximab Followed by Maintenance in Relapsed or Refractory Nhl: Analysis of Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase Ii Trial of Rituximab/Lenalidomide Followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow Up and Correlative Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Refractoriness to Immunochemotherapy in Follicular Lymphoma: Predictive Factors and Outcome

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy